Compare VSAT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | VERA |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 2.9B |
| IPO Year | 1996 | 2021 |
| Metric | VSAT | VERA |
|---|---|---|
| Price | $45.77 | $40.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $46.20 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.34 | N/A |
| Revenue Next Year | $3.59 | $416.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.36 | $18.53 |
| 52 Week High | $52.70 | $56.05 |
| Indicator | VSAT | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 47.53 |
| Support Level | $41.76 | $37.36 |
| Resistance Level | $48.96 | $42.73 |
| Average True Range (ATR) | 3.57 | 2.14 |
| MACD | -0.49 | 0.06 |
| Stochastic Oscillator | 24.91 | 46.17 |
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.